Legal & General Group
CRNX icon

Legal & General Group’s Crinetics Pharmaceuticals CRNX Stock Holding History

Legal & General Group’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.7M Sell
74,355
-13,447
-15% -$601K ﹤0.01% 1787
2025
Q4 		$4.09M Sell
87,802
-6,007
-6% -$267K ﹤0.01% 1671
2025
Q3 		$3.91M Sell
93,809
-3,723
-4% -$119K ﹤0.01% 1697
2025
Q2 		$2.81M Buy
97,532
+8,905
+10% +$275K ﹤0.01% 1827
2025
Q1 		$2.97M Sell
88,627
-312
-0.4% -$11.7K ﹤0.01% 1770
2024
Q4 		$4.55M Buy
88,939
+18,443
+26% +$1.03M ﹤0.01% 1620
2024
Q3 		$3.6M Buy
70,496
+1,738
+3% +$89.6K ﹤0.01% 1724
2024
Q2 		$3.08M Buy
68,758
+4,806
+8% +$222K ﹤0.01% 1759
2024
Q1 		$2.99M Buy
63,952
+9,847
+18% +$385K ﹤0.01% 1757
2023
Q4 		$1.93M Buy
54,105
+502
+0.9% +$15.4K ﹤0.01% 1974
2023
Q3 		$1.59M Buy
53,603
+15,755
+42% +$325K ﹤0.01% 1997
2023
Q2 		$682K Buy
37,848
+15,301
+68% +$305K ﹤0.01% 2352
2023
Q1 		$362K Buy
22,547
+6,601
+41% +$122K ﹤0.01% 2405
2022
Q4 		$292K Buy
15,946
+685
+4% +$12.1K ﹤0.01% 2475
2022
Q3 		$300K Buy
15,261
+831
+6% +$16.9K ﹤0.01% 2476
2022
Q2 		$269K Buy
14,430
+189
+1% +$3.77K ﹤0.01% 2531
2022
Q1 		$313K Buy
14,241
+390
+3% +$7.89K ﹤0.01% 2524
2021
Q4 		$393K Buy
13,851
+4,275
+45% +$105K ﹤0.01% 2489
2021
Q3 		$202K Buy
9,576
+4,483
+88% +$93.8K ﹤0.01% 2689
2021
Q2 		$96K Buy
5,093
+858
+20% +$15.1K ﹤0.01% 2751
2021
Q1 		$64K Buy
4,235
+230
+6% +$3.56K ﹤0.01% 2745
2020
Q4 		$57K Hold
4,005
– – ﹤0.01% 2765
2020
Q3 		$63K Sell
4,005
-1,124
-22% -$17.2K ﹤0.01% 2612
2020
Q2 		$90K Buy
5,129
+3,257
+174% +$55.5K ﹤0.01% 2559
2020
Q1 		$28K Sell
1,872
-390
-17% -$7.99K ﹤0.01% 2784
2019
Q4 		$54K Buy
2,262
+419
+23% +$7.98K ﹤0.01% 2784
2019
Q3 		$28K Hold
1,843
– – ﹤0.01% 2992
2019
Q2 		$46K Buy
1,843
+380
+26% +$9.41K ﹤0.01% 2808
2019
Q1 		$33K Buy
1,463
+410
+39% +$10.1K ﹤0.01% 2884
2018
Q4 		$31K Hold
1,053
– – ﹤0.01% 2886
2018
Q3 		$30K Buy
+1,053
New +$31.3K ﹤0.01% 3023

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Legal & General Group's CRNX Position: Q1 2026 in Review

Legal & General Group reduced its Crinetics Pharmaceuticals (CRNX) stake by 15% in Q1 2026, selling an estimated $601K and leaving 74,355 shares worth $2.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1787.

Legal & General Group first reported a position in CRNX in Q3 2018 and has held it in 31 quarters since. The position peaked at $4.55M in Q4 2024. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Legal & General Group held 74,355 shares of Crinetics Pharmaceuticals worth $2.7M as of Q1 2026.
  • Legal & General Group sold 13,447 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $601K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #1787 holding.
  • Legal & General Group first reported a position in Crinetics Pharmaceuticals in Q3 2018 and has held it in 31 quarters since.
  • Legal & General Group's Crinetics Pharmaceuticals position peaked at $4.55M in Q4 2024.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.